Full-Time

Advanced Wound Care Product Manager

Solventum

Solventum

10,001+ employees

Global healthcare company: wound care, dental

Compensation Overview

$163.2k - $224.4k/yr

+ Variable Incentive Pay

No H1B Sponsorship

Remote in USA

Remote

Remote within the United States.

Bachelor's, MBA

Category
Product (1)
Required Skills
Product Management
Marketing
Financial Modeling

Get referred to Solventum

See people who can refer or advise you

Requirements
  • Bachelor’s degree or higher and 5+ years of experience in upstream or downstream product marketing
  • Must be legally authorized to work in country of employment without sponsorship for employment visa status (e.g., H1B status)
  • Work location: Remote
  • Travel: Less than 25% (domestic/international)
Responsibilities
  • Own marketing strategy and deliverables across multiple high-complexity projects
  • Lead development of target product profiles, value propositions, positioning, and business cases that are financially rigorous and evidence-based
  • Integrate clinical insights into marketing strategy, ensuring product concepts reflect patient outcomes, medical need, and clinical evidence
  • Lead market opportunity analyses, including competitive assessment, market potential, and unmet need identification
  • Prioritize geographic launch markets based on commercial potential, regulatory pathway, and operational readiness
  • Build out robust business cases, including revenue projections, NPV analyses, cost of goods considerations, and pricing strategies
  • Partner with Finance to model project scenarios and assess financial impact of strategic choices
  • Identify risks and opportunities that may impact financial, clinical, or operational outcomes
  • Serve as the primary marketing liaison on the new product core team
  • Align marketing inputs with cross-functional plans, timelines, and operational constraints
  • Collaborate with PMO to ensure stage-gate readiness
  • Partner with Global Downstream and Regional Marketing to provide launch readiness input, market prioritization guidance, and go-to-market strategy alignment
  • Work with R&D, regulatory, and Medical Affairs to ensure clinical feasibility, safety, and evidence integration
  • Coordinate with Supply Chain and R&D to assess cost of goods assumptions, product availability, scale up needs, and global launch readiness
Desired Qualifications
  • Advanced degree (e.g., MBA, Economics, or related field)
  • Experience in medical devices, medtech, healthcare, or similar regulated industry
  • Experience with stage-gate processes and tools
  • Strong financial and business case acumen, including revenue modeling, NPV analyses, and pricing strategies
  • Track record of collaborating cross-functionally to deliver actionable recommendations
  • Excellent strategic thinking, problem-solving, analytical, and communication skills
  • Knowledge of the advanced wound care market, including negative pressure wound therapies
  • Ability to thrive in an action-oriented and high accountability environment

Solventum provides a wide range of healthcare products across four main areas: wound care and surgical supplies, dental and orthodontic tools, health information software, and purification filters for biopharmaceuticals. These products work by combining material science and data science to help hospitals manage patient records, prevent infections during surgery, and filter fluids for medical treatments like dialysis. Unlike many competitors, the company holds a massive portfolio of over 7,300 patents inherited from its history as a 3M division, allowing it to serve over 75% of U.S. hospitals. Its goal is to use this intellectual property and a disciplined business model to find new solutions for healthcare providers and grow within the global medical technology market.

Company Size

10,001+

Company Stage

IPO

Headquarters

Maplewood, Minnesota

Founded

2023

Get referred to Solventum

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Solventum raised 2026 EPS guidance to $7.10-$7.20 after Q2 beat on August 5.
  • Management targets higher-margin MedTech focus after separating HIS and exiting noncore businesses.
  • Thermo Fisher's Purification deal and Acera Surgical acquisition sharpen portfolio and capital allocation.

What critics are saying

  • Q3 2026 revenue will reverse after $125 million ERP pull-forward, compressing growth.
  • HIS separation could fail within 18 months if regulators, boards, or markets balk.
  • AI competitors can undercut HIS workflows; that unit still supplied 16.3% of 2025 sales.

What makes Solventum unique

  • Solventum owns 7,300 patents and 75% U.S. hospital HIS penetration on August 5, 2026.
  • Its wound care and sterilization franchises drove Q2 2026 growth despite ERP disruption.
  • The $200 million Eagan Innovation Hub deepens R&D across MedSurg, dental, and digital health.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

5%

2 year growth

8%
Yahoo Finance
Aug 11th, 2026
Solventum beats Q2 estimates with $2.21B revenue, raises EPS guidance 10% amid HIS separation

Healthcare solutions provider Solventum reported second quarter revenue of $2.21 billion, up 2.2% year on year and ahead of analyst estimates of $2.15 billion. Non-GAAP profit of $2.55 per share beat consensus estimates by 33.8%. The company announced plans to separate its Health Information Systems business to focus on its MedSurg and Dental segments. Management said the move would allow the HIS unit to pursue AI-driven innovation whilst sharpening Solventum's focus as a pure-play MedTech company. Second quarter results were temporarily boosted by approximately $125 million in advanced orders placed ahead of a major ERP system transition, which management expects to reverse next quarter. The company raised its full-year adjusted EPS guidance to $7.15 at the midpoint, a 10% increase. Solventum is nearing completion of its separation from 3M.

Yahoo Finance
Aug 9th, 2026
Solventum raises 2026 outlook with 9.5% Q2 growth boosted by $125M advanced orders and $100M tariff refund

Solventum exceeded expectations in Q2, posting $2.2 billion in sales with 9.5% organic growth. However, this included roughly $125 million in advanced ERP-related orders and a $100 million tariff refund. Excluding these benefits, organic growth was approximately 4% and adjusted EPS was estimated at $1.73. The company raised its 2026 outlook, now expecting 2.5%–3% organic sales growth, a 22.2%–22.7% operating margin, adjusted EPS of $7.10–$7.20, and free cash flow of $200 million–$300 million. Third-quarter growth is expected to decline temporarily as the advanced orders reverse. Solventum also announced plans to separate its Health Information Systems business through a potential spin-off or sale, aiming to focus on its MedSurg and Dental segments.

PR Newswire
Aug 5th, 2026
Solventum Q2 sales up 9.5%, raises 2026 guidance and plans to separate Health Information Systems unit

Solventum reported second quarter 2026 sales of $2.2 billion, up 2.2% on a reported basis and 9.5% organically. The MedTech company posted GAAP diluted earnings per share of $0.53 and adjusted diluted EPS of $2.55, marking a 50.9% increase. Operating cash flow reached $227 million, whilst free cash flow totalled $144 million. The strong performance was driven by volume and product mix across all segments, including advance orders ahead of ERP cutovers. Solventum announced plans to separate its Health Information Systems business segment as part of its transformation strategy. The company raised its full-year 2026 guidance, increasing organic sales growth to 2.5% to 3.0%, adjusted EPS to $7.10 to $7.20, and free cash flow to $200 million to $300 million.

Yahoo Finance
Aug 2nd, 2026
Solventum appoints Neil Zieselman as chief accounting officer

Solventum has appointed Neil Zieselman as Senior Vice President, Controller, and Chief Accounting Officer. He will succeed Mary Wilcox, who is retiring. Zieselman brings experience from Surgery Partners, Stryker Corporation, Covanta Holding Corporation, Cendant Corporation, and Avaya. He is a licensed CPA. The company's stock trades at $85.44. It has delivered a 9.5% return over the past week and 19.1% over the past year. For investors, Zieselman's background in healthcare and corporate finance may influence Solventum's financial controls, reporting quality, and regulatory engagement. His approach could shape disclosure practices and capital allocation commentary in future earnings calls. Interest payments are not well covered by earnings, making any changes under the new Chief Accounting Officer particularly important for risk assessment.

Yahoo Finance
Jun 22nd, 2026
Solventum gains 12% in three months but lags healthcare sector over the year

Solventum, a healthcare company spun off from 3M Company, has underperformed the broader healthcare sector over the past year despite recent gains. The stock trades 14.5% below its 52-week high of $88.20 reached in December 2025. Whilst SOLV shares climbed 12.4% over the past three months compared to the State Street Health Care Select Sector SPDR ETF's 1.5% gain, the longer-term picture shows divergence. Over 52 weeks, Solventum gained 3.9% whilst the healthcare ETF advanced 12.1%. Year-to-date, SOLV has fallen 4.8% versus the sector's 3.5% decline. The company beat Q1 FY2026 expectations on 5 May, with revenue of $2.01 billion and adjusted EPS of $1.48. Management expects nearly 20 new product launches over two years.